Advanced Biomed Unveils Innovative A+PerfusC™ 3D Cell Culture
Advanced Biomed Inc. Introduces A+PerfusC 3D Cell Culture System
Advanced Biomed Inc. (Nasdaq: ADVB), a pioneering biotechnology firm focused on cutting-edge biomedical technologies, has just launched its newest offering, the A+PerfusC™ system. This innovative platform is a compact, all-in-one solution designed to support perfusion 3D cell culture, aimed to enhance the accuracy and effectiveness in precision medicine and drug discovery.
What is the A+PerfusC™ System?
The A+PerfusC™ system is engineered to replicate human physiological conditions in vitro, allowing researchers to closely observe and interact with cell cultures in real-time. This unique system integrates automated perfusion with environmental controls, efficiently operating up to 12 days of continuous culture. By minimizing human error and potential contamination, the A+PerfusC™ significantly improves reliability in experimental results.
Key Features of A+PerfusC™
The A+PerfusC™ system boasts several impressive features that make it invaluable to researchers:
- Eight independent channels to support multiple patient sources simultaneously.
- Capable of generating 600 tumor spheroids per row for each patient, with an impressive total of 4,800 spheroids per plate.
- Designed for seamless integration into existing 96 or 384 well plates for high-throughput drug screening.
- Easy compatibility with various microscopy platforms for enhanced observation.
- Expandable platform that can support up to four incubators, providing scalability for large projects.
Advancements in Biomedical Research
Advanced Biomed has indicated that the A+PerfusC™ system has already passed rigorous internal testing and is in the process of mass production development. As the company works on finalizing this stage, they are establishing quality control standards to ensure that the product meets industry expectations.
Broader Applications in Healthcare
The applications of the A+PerfusC™ platform are diverse and include areas such as personalized oncology, in vitro drug screening, regenerative medicine, organoid research, and stem cell studies. The global 3D cell culture market, projected to exceed USD 4.71 billion in the coming years, reflects the growing necessity for advanced cell culture systems in various biomedical research fields.
Expert Insights from Advanced Biomed
Dr. Yi Lu, the CEO of Advanced Biomed, shared insights on the limitations of traditional static cell culture methods, which often lead to nutrient delivery disparities and waste accumulation. He emphasized how the A+PerfusC™ system overcomes these challenges by facilitating even nutrient distribution and waste clearance, improving cell viability, and better mimicking human tissue complexity.
Dr. Lu stated, “Our 3D culture system is designed to deliver nutrients evenly and remove waste effectively, emphasizing the necessity for a solution that not only enhances cell viability but also improves reproducibility in research findings.”
Future Aspirations
Looking ahead, Advanced Biomed plans to enhance the A+PerfusC™ system for high-throughput applications, incorporating imaging capabilities paired with AI-driven analytics for more precise tumor profiling, refined cell therapies, and the development of personalized medicine approaches.
About Advanced Biomed Inc.
Founded in Nevada, Advanced Biomed Inc. specializes in innovative biomedical technologies focused on cancer detection and precision medicine. The company's subsidiaries in Taiwan, Hong Kong, and Mainland China are instrumental in developing proprietary microfluidic platforms that combine semiconductor technology and biotechnology for advanced detection and analysis of circulating tumor cells (CTCs).
This advanced system aims to provide solutions for cancer screening, diagnosis, treatment selection, and prognosis assessment, all while navigating regulatory clearances and pursuing global growth strategies.
Frequently Asked Questions
What is the A+PerfusC™ system?
The A+PerfusC™ system is an integrated perfusion 3D cell culture platform designed to mimic human physiological conditions, improving research reliability.
What are the main features of the A+PerfusC™ system?
Key features include multiple channels for patient sources, high spheroid production, seamless integration for drug screening, and compatibility with microscopy platforms.
What potential applications does the system have?
It can be used in personalized oncology, in vitro drug screening, regenerative medicine, organoid studies, and stem cell research.
Who is the CEO of Advanced Biomed Inc.?
The current CEO is Dr. Yi Lu, who has emphasized the importance of the A+PerfusC™ system in enhancing cell cultures.
Where can I find more information about Advanced Biomed?
For additional details, please visit their official website at www.advanbiomed.com.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
